Saito Kei 齋藤圭

Researcher Number	20815617
Other IDs
Affiliation (Current)	2025: 日本大学, 医学部, 准教授 2025: 東京大学, 医学部附属病院, 届出研究員
Affiliation (based on the past Project Information) *help	2022: 東京大学, 医学部附属病院, 届出研究員 2020 – 2021: 東京大学, 医学部附属病院, 助教
Review Section/Research Field	Principal Investigator Basic Section 49010:Pathological biochemistry-related
Keywords	Principal Investigator 膵癌 / 膵がん

Comprehensive analyses about factors involved in the progression from IPMN to Pancreatic cancerPrincipal Investigator
- Principal Investigator
  
  Saito Kei
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 49010:Pathological biochemistry-related
- Research Institution
  The University of Tokyo

All 2023 2022 2021 2020

All Journal Article

[Journal Article] Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study2023
- Author(s)
  Suzuki Yukari、Saito Kei、Nakai Yousuke、Oyama Hiroki、Kanai Sachiko、Suzuki Tatsunori、Sato Tatsuya、Hakuta Ryunosuke、Ishigaki Kazunaga、Saito Tomotaka、Hamada Tsuyoshi、Takahara Naminatsu、Tateishi Ryosuke、Fujishiro Mitsuhiro
- Journal Title
  
  Supportive Care in Cancer
  
  Volume: 31 Issue: 3 Pages: 197-197
- DOI
  10.1007/s00520-023-07659-w
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K15958, KAKENHI-PROJECT-20K08324, KAKENHI-PROJECT-20K08353, KAKENHI-PROJECT-20K16154, KAKENHI-PROJECT-23K07392
[Journal Article] MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages2022
- Author(s)
  Kato H, Tateishi K, Fujiwara H, Nakatsuka T, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi H, Otsuka M, Iwadate D, Oyama H, Kanai S, Noguchi K, Suzuki T, Sato T, Hakuta R, Ishigaki K, Saito K, Saito T, Takahara N, Kishikawa T, Hamada T, Takahashi R, Miyabayashi K, et al.
- Journal Title
  
  Gastroenterology
  
  Volume: 162 Issue: 4 Pages: 1272-1287
- DOI
  10.1053/j.gastro.2021.12.254
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K08362, KAKENHI-PROJECT-19K08435, KAKENHI-PROJECT-19K16533, KAKENHI-PROJECT-20K08353, KAKENHI-PROJECT-21K07886, KAKENHI-PROJECT-21K07935, KAKENHI-PROJECT-20K16154, KAKENHI-PROJECT-21K15368, KAKENHI-PROJECT-16H06279, KAKENHI-PROJECT-21K07906, KAKENHI-PROJECT-22K06976, KAKENHI-PROJECT-20K08324, KAKENHI-PROJECT-21K15966
[Journal Article] ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms2021
- Author(s)
  Hamada T, Oyama H, Nakai Y, Tada M, Koh H, Tateishi K, Arita J, Hakuta R, Ijichi H, Ishigaki K, Kawaguchi Y, Kogure H, Mizuno S, Morikawa T, Saito K, Saito T, Sato T, Takagi K, Takahara N, Takahashi R, Tanaka A, Tanaka M, Ushiku T, Hasegawa K, Koike K.
- Journal Title
  
  Cancer Epidemiol Biomarkers Prev .
  
  Volume: 30 Pages: 1020-1028
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K16154
[Journal Article] A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel2020
- Author(s)
  Saito Kei、Nakai Yousuke、Takahara Naminatsu、Ishigaki Kazunaga、Suzuki Yukari、Inokuma Akiyuki、Noguchi Kensaku、Kanai Sachiko、Sato Tatsuya、Hakuta Ryunosuke、Saito Tomotaka、Hamada Tsuyoshi、Mizuno Suguru、Kogure Hirofumi、Ijichi Hideaki、Tateishi Keisuke、Koike Kazuhiko
- Journal Title
  
  Investigational New Drugs
  
  Volume: 39 Issue: 2 Pages: 605-613
- DOI
  10.1007/s10637-020-01022-0
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K16154

1. TATEISHI Keisuke

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
2. 濱田毅

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
3. 石垣和祥

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Saito Kei 齋藤圭

Research Projects

Research Products

Co-Researchers

Comprehensive analyses about factors involved in the progression from IPMN to Pancreatic cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms2021

Author(s)

Journal Title

Data Source

[Journal Article] A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel2020

Author(s)

Journal Title

DOI

Data Source

Saito Kei 齋藤 圭

Research Projects

Research Products

Co-Researchers

Comprehensive analyses about factors involved in the progression from IPMN to Pancreatic cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms2021

Author(s)

Journal Title

Data Source

[Journal Article] A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel2020

Author(s)

Journal Title

DOI

Data Source

Saito Kei 齋藤圭